Psychomotor Performance Relevant to Driving Ability in Patients with Schizophrenia Treated with Haloperidol and Aripiprazole.
10.16946/kjsr.2012.15.2.99
- Author:
Ji Hyun HAN
;
Se Jin PARK
;
Jong Il LEE
;
An Kee CHANG
;
Shi Hyun KANG
;
Minah SOH
;
Kyung Jin LEE
;
Eun Sang KOH
;
Sungwon ROH
- Publication Type:Original Article
- Keywords:
Schizophrenia;
Haloperidol;
Aripiprazole;
Driving;
Psychomotor performance
- MeSH:
Antipsychotic Agents;
Automobile Driving;
Haloperidol;
Humans;
Imidazoles;
Nitro Compounds;
Piperazines;
Psychomotor Performance;
Quinolones;
Sample Size;
Schizophrenia;
Aripiprazole
- From:Korean Journal of Schizophrenia Research
2012;15(2):99-105
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: This study aimed to compare psychomotor performance related with automobile driving in patients with schizophrenia under the treatment of a typical antipsychotic agent, haloperidol, or an atypical antipsychotic agent, aripiprazole. METHODS: We evaluated driving ability of schizophrenia patients by using the cognitive perceptual assessment for driving (CPAD). Twelve patients receiving haloperidol monotherapy and 18 taking aripiprazole monotherapy participated in this study and the results of CPAD were compared with each other. RESULTS: Of 30 participants, 15 (50%) of the patients passed the CPAD to be regarded as competent to drive, 3 (10%) of the patients failed the CPAD considered to be severely impaired. Controlling for sex, age, education, duration of illness, there were no significant differences in the CPAD results between two treatment groups. We observed a trend that patients who received aripiprazole showed a higher total score of the CPAD than haloperidol-treated patients (55.2+/-4.9 vs. 45.7+/-8.4, p=0.080). CONCLUSION: There were no significant differences in the psychomotor performance relevant to driving ability between haloperidol and aripiprazole groups. But our results suggest that aripiprazole might have the neurocognitive advantage over haloperidol. Future study with a large sample size and diverse antipsychotics is warranted.
